Shares of Alimera Sciences Inc. (NASDAQ:ALIM) dropped 1.4% on Friday . The stock traded as low as $1.85 and last traded at $2.04, with a volume of 2,805,753 shares traded. The stock had previously closed at $2.07.

ALIM has been the topic of several recent research reports. Zacks Investment Research upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Monday, May 9th. Cowen and Company downgraded Alimera Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 5th.

The firm’s market cap is $92.45 million. The stock’s 50-day moving average is $1.42 and its 200-day moving average is $1.82.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. The business had revenue of $5.80 million for the quarter, compared to analyst estimates of $5.83 million. Alimera Sciences’s revenue was up 48.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) earnings per share. Equities analysts anticipate that Alimera Sciences Inc. will post ($0.73) earnings per share for the current fiscal year.

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.